BIO-KEY INTERNATIONAL INC (BKYI)

US09060C5076 - Common Stock

2.095  +0.69 (+48.58%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to BKYI. BKYI was compared to 280 industry peers in the Software industry. BKYI has a bad profitability rating. Also its financial health evaluation is rather negative. BKYI does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

BKYI had negative earnings in the past year.
BKYI had a negative operating cash flow in the past year.
In the past 5 years BKYI always reported negative net income.
In the past 5 years BKYI always reported negative operating cash flow.

1.2 Ratios

BKYI has a worse Return On Assets (-142.02%) than 93.19% of its industry peers.
BKYI's Return On Equity of -6831.79% is on the low side compared to the rest of the industry. BKYI is outperformed by 88.53% of its industry peers.
Industry RankSector Rank
ROA -142.02%
ROE -6831.79%
ROIC N/A
ROA(3y)-107.41%
ROA(5y)-189.86%
ROE(3y)-352.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 14.78%, BKYI is doing worse than 86.74% of the companies in the same industry.
BKYI's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BKYI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.43%
GM growth 5YN/A

More info and screens

1

2. Health

2.1 Basic Checks

BKYI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BKYI has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BKYI has less shares outstanding
BKYI has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -31.59, we must say that BKYI is in the distress zone and has some risk of bankruptcy.
BKYI has a worse Altman-Z score (-31.59) than 96.06% of its industry peers.
A Debt/Equity ratio of 16.90 is on the high side and indicates that BKYI has dependencies on debt financing.
BKYI has a worse Debt to Equity ratio (16.90) than 88.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 16.9
Debt/FCF N/A
Altman-Z -31.59
ROIC/WACCN/A
WACC11.15%

2.3 Liquidity

BKYI has a Current Ratio of 0.78. This is a bad value and indicates that BKYI is not financially healthy enough and could expect problems in meeting its short term obligations.
BKYI has a worse Current ratio (0.78) than 84.59% of its industry peers.
A Quick Ratio of 0.71 indicates that BKYI may have some problems paying its short term obligations.
With a Quick ratio value of 0.71, BKYI is not doing good in the industry: 86.38% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.78
Quick Ratio 0.71

More info and screens

1

3. Growth

3.1 Past

BKYI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -344.95%.
Looking at the last year, BKYI shows a very negative growth in Revenue. The Revenue has decreased by -25.56% in the last year.
BKYI shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.93% yearly.
EPS 1Y (TTM)-344.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.06%
Revenue 1Y (TTM)-25.56%
Revenue growth 3Y39.77%
Revenue growth 5Y13.93%
Sales Q2Q%18.03%

3.2 Future

The Earnings Per Share is expected to decrease by -33.91% on average over the next years. This is quite bad
The Revenue is expected to decrease by -7.80% on average over the next years.
EPS Next Y-113.79%
EPS Next 2Y-33.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-22.48%
Revenue Next 2Y-7.8%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BKYI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BKYI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

BKYI's earnings are expected to decrease with -33.91% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.91%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BKYI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIO-KEY INTERNATIONAL INC

NASDAQ:BKYI (12/30/2024, 2:11:07 PM)

2.095

+0.69 (+48.58%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners4.95%
Inst Owner Change1225.83%
Ins Owners5.53%
Ins Owner Change2.72%
Market Cap6.56M
Analysts82.86
Price Target3.06 (46.06%)
Short Float %1.35%
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-23.74%
Min EPS beat(2)-81.55%
Max EPS beat(2)34.08%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-5.6%
Min Revenue beat(2)-42.62%
Max Revenue beat(2)31.42%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)16.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)13.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.03
P/FCF N/A
P/OCF N/A
P/B 49.29
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-10.12
EYN/A
EPS(NY)-1.59
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.26
OCFYN/A
SpS2.04
BVpS0.04
TBVpS-0.33
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.02%
ROE -6831.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.78%
FCFM N/A
ROA(3y)-107.41%
ROA(5y)-189.86%
ROE(3y)-352.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-36.43%
GM growth 5YN/A
F-Score3
Asset Turnover1
Health
Industry RankSector Rank
Debt/Equity 16.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.05%
Cap/Sales 0.38%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.78
Quick Ratio 0.71
Altman-Z -31.59
F-Score3
WACC11.15%
ROIC/WACCN/A
Cap/Depr(3y)11.68%
Cap/Depr(5y)11.43%
Cap/Sales(3y)0.65%
Cap/Sales(5y)0.93%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-344.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.06%
EPS Next Y-113.79%
EPS Next 2Y-33.91%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-25.56%
Revenue growth 3Y39.77%
Revenue growth 5Y13.93%
Sales Q2Q%18.03%
Revenue Next Year-22.48%
Revenue Next 2Y-7.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.12%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.6%
OCF growth 3YN/A
OCF growth 5YN/A